Profilo
Tina Abild Olesen is currently Vice Chairman at World Diabetes Foundation, Managing Director at Novo Nordisk Pharma GmbH, and Director at Embla Medical hf since 2024.
Formerly, Ms. Olesen was Senior Vice President-Global Diabetes Franchise at Novo Nordisk A from 2022 to 2025.
Education includes graduate and MBA degrees from Copenhagen Business School.
Posizioni attive di Tina Olesen
| Società | Posizione | Inizio |
|---|---|---|
| EMBLA MEDICAL HF. | Direttore/Membro del Consiglio | 01/03/2024 |
Novo Nordisk Pharma GmbH
Novo Nordisk Pharma GmbH Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products | Amministratore Delegato | - |
World Diabetes Foundation
World Diabetes Foundation Investment Trusts/Mutual FundsMiscellaneous Functions as a foundation or endowment | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Tina Olesen
| Società | Posizione | Fine |
|---|---|---|
| NOVO NORDISK A/S | Corporate Officer/Principal | 01/08/2025 |
Formazione di Tina Olesen
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 5 |
|---|---|
Novo Nordisk A/S
Novo Nordisk A/S Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for diabetes care | Health Technology |
Novo Nordisk Pharma GmbH
Novo Nordisk Pharma GmbH Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products | Health Technology |
Embla Medical hf
Embla Medical hf Medical SpecialtiesHealth Technology Provides non-invasive orthopedic products and support services | Health Technology |
Copenhagen Business School
Copenhagen Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
World Diabetes Foundation
World Diabetes Foundation Investment Trusts/Mutual FundsMiscellaneous Functions as a foundation or endowment | Miscellaneous |
















